HEB News and Press, Hemispherx BioPharma Inc. From 02/12/19

To be a stockholder of record, investors are advised to own Hemispherx stock by 4:00 PM ET, Tuesday, February 12, 2019 to account for T+2 settlement timing Record date established as Thursday, February 14, 2019 OCALA, Fla., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, I...

OCALA, Fla., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical needs in immunology and oncology, announced today the start at the UPMC Hillman Cancer Center in Pittsburgh, PA of a new clinical study supported...

OCALA, Fla., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today provided an updat...

OCALA, Fla., Jan. 31, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. CEO Tom Equels this week provided investors at NobleConXV with an update on the company’s ongoing work in immuno-oncology and in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome...

The following slide deck was published by Hemispherx Biopharma, Inc in conjunction with this Read more ...

NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Chemours Company (NYSE:CC), Inter Parfums, Inc. (NASDAQ:IPAR), Newmon...

OCALA, Fla., Jan. 24, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that CEO Thomas K. Equels will present at NobleConXV ȁ...